The BARF Project: A Pilot Study Using the BARF Scale to Assess CINV in Children

Washington University School of Medicine6 enrolled

Overview

In this pilot study, the Baxter Retching Faces (BARF) Scale will be used to assess chemotherapy induced nausea and vomiting (CINV) in the pediatric cancer population during chemotherapy admissions, and the corresponding administration of anti-emetic medications will be reviewed.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Enrollment

Conditions

Nausea

Interventions

Baxter Retching Faces (BARF) scaleBEHAVIORAL

* Pictorial scale that was developed for use by pediatric patients in self-reported assessments of nausea severity * A patient will respond by choosing a picture or a number on the scale that best represents how they feel. The patient may speak or simply point to their response. While the numbers 0-2-4-6-8-10 are listed alongside the pictures, patients are also allowed to choose "in between" or odd numbers. If a patient is unwilling to participate, the patient's parent or guardian may serve as their proxy and choose a number for them, based off of their symptoms. * The BARF scale has 6 faces with assigned scores ranging from 0 to 10 with a score difference of 2 between each face (a higher score indicates more nausea).

Eligibility

Sex: ALLMin age: 4 YearsMax age: 12 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with cancer of any kind. * Patients receiving inpatient chemotherapy at SLCH on the general pediatric oncology service * Patients admitted for a course of inpatient chemotherapy scheduled to last at least 24 hours and but no more than 7 days. * Patients who have received any prior cancer treatment, including radiation therapy, and/or surgery. * Patients ages 4 to 12 years of age. * Patient with a guardian who has the ability to understand English and the willingness to sign an IRB approved written informed consent document. Exclusion Criteria: * Any patient who is not undergoing inpatient chemotherapy on the general pediatric oncology service, including patients undergoing chemotherapy as conditioning for hematopoietic stem cell transplantation or other cellular therapy. * Any patient who is receiving their first cycle of inpatient chemotherapy (however, they can be included during a future cycle). * Any patient who is blind or unable to communicate by speaking or pointing.

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Doses of anti-emetic medication administered during inpatient chemotherapy admissions

Time frame: 24 hours - 7 days (estimated)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.